MiOra’s Post

#FOPPRinPMWC24 #AlzheimerBloodTesting It was an immense honor to meet with Dr. Prasun Mishra, a distinguished leader in life science and healthcare innovation. With an illustrious career contributing to prestigious institutions such as Genentech, Roche, Rutgers University, NCI, NIH, and the U.S. Department of Health and Human Services, Dr. Mishra has helped shape the landscape of modern healthcare through his numerous publications, patents, and his role in drug development and approvals. His commitment to scientific excellence is evident, being honored with over 40 prestigious awards and more than 50 keynote talks. Our conversation was particularly enlightening as we discussed the latest advancements in #Alzheimer's #blood testing and precision healthcare—a field that is rapidly evolving and one that our company, Instant NanoBiosensors is deeply involved in. I am grateful for the introduction by Sibylle Hauser and the opportunity to engage in such a thought-provoking exchange with Dr. Mishra. The insights gained from our discussion are invaluable and will undoubtedly influence our continued work in pushing the envelope in medical science and technology. #HealthcareInnovation #AlzheimersResearch #PrecisionMedicine #LifeSciences #ScientificExcellence #phosphorylation #Ptau #Ph#alzheimersdisease #UltraSensitivityDetection #PostTranslationalModifications #PTMs

Continuing my commitment to advancing clinical knowledge, I had the privilege of attending the UK Pharmacogenetic and Stratified Medicine Network conference on 26 June 2024 in London. This comprehensive event offered an insightful exploration into the rapidly evolving field of stratified medicine, which holds immense promise for the future of personalized healthcare. The sessions provided an in-depth analysis of the opportunities that stratified medicine presents—particularly in optimizing therapeutic interventions tailored to individual genetic profiles. However, the discussions also highlighted the significant challenges that remain, including the complexities of integrating pharmacogenetics into routine clinical practice, navigating regulatory frameworks, and addressing gaps in evidence across diverse populations. Despite the hurdles, the potential of stratified medicine to transform patient care is undeniable, underscoring the need for refining research objectives to generate more precise, actionable outcomes. I look forward to applying these insights to future research efforts and contributing to the ongoing development of this transformative field. #Pharmacogenetics #StratifiedMedicine #PersonalizedHealthcare #PrecisionMedicine #ClinicalResearch #ContinuousLearning #MedicalInnovation #UKPharmacogeneticNetwork #LondonConference 

Yup - #KRASholes are a world wide problem!! Those barriers, gaps in Healthcare Outcomes Literacy & Equity we know they exist, I'm delighted to be on this Global Summit with difference makers! Join me on May 1st for an open panel discussion to address these holes the advancement of precision medicine. This virtual global summit will share and open for discussion the solutions and recommendations proposed by the ‘Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum’. Composed of leading experts in the precision medicine field, our shared aim is to provide the industry and policy makers with valuable and clear economic guidance and recommendations to overcome the challenges obstructing the advancement of precision medicine. Register for free using the link https://lnkd.in/edPcGVNX #PrecisionMedicine #KnowKRAS #HealthcareInnovation

This May is dedicated to ALS Awareness. Redenlab scientists continue working towards strengthening evidence for tracking treatment response in ALS with pharma and international consortia. Our involvement in ALS natural history studies and an understanding of what matters to regulators can aid further clinical outcomes. ALS is a severe disease affecting brain areas essential for communication and safe eating, with varying motor speech deficits influenced by progression rate, genetic factors, and initial impairment site, and new treatments are being trialed annually. Redenlab's experience in FDA Type C and EMA CHMP meetings can assess the suitability of clinical outcomes for efficacy trials. They understand that not all COAs are equal and that the study phase can influence the appropriateness of different outcomes. At the cutting edge of research for ALS, Redenlab has partnered with the insitutions of the University of Melbourne and The University of Queensland. For more information, please visit https://lnkd.in/giYFYpYa. #Research #Study #Speech #ALS #ALSAwareness

Yesterday, during the Global Summit on Precision Medicine, we had a thought-provoking discussion. Now, it's time for all attendees and those committed to personalized medicine to take action on our findings regarding current practice gaps. These gaps keep patients from receiving necessary treatments and care, and we must implement our recommendations to improve health for all. Together, we can make a difference. Thanks to my co-chair Susanne Munksted, Peter Keeling, the Diaceutics PLC team, our Forum members, and guest panelists for making a great event. We have a rich set of data and recommendations to utilize now. #rednucleus #personalizedmedicine #precisiondiagnostics #personalizedmedicinecoalition

I had the pleasure of attending the SOCRA Houston Galveston Chapter virtual meeting where Scott Wehage, Founder/President of APEX Clinical Research Consulting, LLC, presented on "Clinical Trials in Functional/Personalized Medicine." It was an insightful session shedding light on the future of clinical research in this rapidly evolving field. The presentation provided insightful information on various aspects of functional and personalized medicine, delving into the intricate connections among genetics, environment, and lifestyle in shaping individual health outcomes. I found the discussion on the pivotal role of biomarkers and advanced diagnostics in guiding personalized treatment strategies to be especially interesting and believe that it has the potential to challenge the current conventional methods in drug and device trials, thereby facilitating healthcare delivery transformation and improving patient outcomes significantly. Thank you Scott Wehage and Aryn Knight, BS, CCRP (Memorial Hermann Health System) for providing such enlightening insights. #HealthcareInnovation #ResearchInsights #ClinicalTrials #Biomarkers #AdvancedDiagnostics #Genetics #LifestyleMedicine #PrecisionMedicine #HealthTech #MedicalResearch #PatientCare #HealthcareTech #DigitalHealth #InnovativeHealthcare #HealthcareLeadership #ContinuousLearning #ProfessionalDevelopment #socrahouston #socra #northeasternuniversity #ProfessionalDevelopment #RAStudents #LifeSciencesCareers #RAOpportunitiesUSA #northeasternuniversity 

Semiofest 2024 is one week away! I am excited to join Luminous thought leaders and accomplished semioticians Malcolm Evans, Natasha Delliston, and Yogi Hendlin to present on "Biosemiotics: Methodologically Evolving Applied Semiotics to Account for More Experiences, Deepen Relationships, and Transform Systems." We will discuss the evolution of applied #semiotics to tackle complex health issues while enhancing R&D, product development and commercial strategy in the #lifesciences. We endorse an evolved model of semiotics, one that builds on the depth of cultural and psychological insight to include biology - from physiology and biochemistry, to clinical treatment and care. We will showcase this through recent #biopharma examples in #obesity and GLP 1s, #raredisease, neurological disease, and more. The application of semiotics has helped the CPG industry innovate, and holds enormous promise for manufacturers of medicines and devices. If you would like a sneak peek, check out our recent panel Society for Applied Anthropology here: https://lnkd.in/dvtr8P3R Semiofest agenda here: https://lnkd.in/ew8tpSa2

In his book, Henry Chesbrough defines #openinnovation as “the use of purposive inflows and outflows of knowledge to accelerate internal innovation, and expand the markets for external use of innovation.” This aligns with being an #ambidextrous organization, akin to Janus, the Roman god with eyes in the front and back. These concepts of osmosis and permeability help lighten rigid corporate walls and strengthen the building. Key aspects of open innovation: -Adapt and Align: Quickly seize new opportunities to adapt to volatile markets and avoid complacency. -Value Creation: Clearly define short-term value and coordinate activities to deliver it effectively. Here 3 Examples in the Pharmaceautical industry which I find particularly interesting: -Angelini Pharma and Wazoku Crowd: Angelini Pharma launched an open innovation challenge focused on epilepsy. The initiative seeks novel solutions for epilepsy management, leveraging the Wazoku Crowd platform to gather ideas from external innovators. -Roche and GOSH: Roche and Great Ormond Street Hospital (GOSH) collaborate to advance personalized healthcare for children. Their partnership focuses on integrating genomic data with clinical care to create tailored treatments. -Novo Nordisk’s Science to Medicine ValidatioNN: This program invites scientists and researchers to collaborate on early-stage research. This initiative supports innovations in diabetes, obesity, and other chronic diseases, aiming to turn scientific ideas into practical medical solutions. Embracing open innovation allows pharmaceutical companies to harness external expertise and accelerate the development of groundbreaking therapies. Link in comments!

Looking forward to showcase our research at the Global Evidence Summit 2024 in Prague: Oral presentations: Christoffer Bruun Korfitsen: "Policies and practices on conflicts of interest of editors and peer reviewers in medical journals: cross-sectional study", 10 September 11:00-12:00, Oral sessions: Ensuring Research Integrity 1, Hall D2 David Ruben Teindl Laursen: "The impact of active placebo control groups on estimated intervention effects in pharmacological randomised trials: a meta-epidemiological study", 13 September 11:00-12:00, Oral sessions: Diverse aspects of Research Integrity and accessible evidence, Hall D5 Helena Van Beersel Krejčíková: "Conflicts of interest in research across scholarly disciplines: cross-sectional study and qualitative content analysis of policies", 13 September 11:00-12:00, Oral sessions: Ensuring Research Integrity 2, Hall D7 Posters: Mette Bangshof Engmose: "Exploration of factors associated with variability in adherence to SPIRIT 2013 and CONSORT 2010 – a systematic review", 11 September, Poster Area Mathias Weis Damkjær: “Mapping review on regulation, implementation and postmarket surveillance of medical devices", 12 September, Poster Area Meetings:  Cochrane Bias Methods Group annual meeting 2024, 10 September 12:45-13:45, including co-convenor Asbjørn Hrobjartsson informing on the updated SPIRIT 2024 and CONSORT 2024 reporting guidelines, Hall D9 #GES2024 #ConflictsOfInterest #ActivePlacebo #ReportingGuidelines #CONSORT #SPIRIT #Devices #Bias

I’m thrilled to announce that I’ve officially completed my PhD! This milestone is more than just an academic achievement; it’s the culmination of a deeply personal and transformative journey. My passion for metabolic health research was sparked by a poignant family experience. Watching my grandmother, bedridden and battling diabetes, struggle with managing her condition highlighted the urgent need for better solutions. Her challenges and eventual complications fueled my determination to improve patient care in this critical area. While we’ve made strides in treating metabolic conditions, a significant gap remains in non-invasive methods for monitoring endogenous insulin production—a crucial aspect of personalized diabetes management. This gap is more than a technical hurdle; it’s a barrier to enhancing patient outcomes and quality of life. My research aims to bridge this gap by developing a cutting-edge, home-based self-testing device that utilizes urinary biomarkers to monitor metabolic health. This innovative approach is designed to be less intrusive, more accessible, and potentially transformative for patients who face frequent hospital visits. Our goal is to redefine metabolic health management, contributing to a more effective and patient-friendly solution for monitoring and preventing conditions like diabetes. Also, I want to extend my heartfelt gratitude to everyone who supported me along the way— my supervisors and co-supervisors (to Prof. Dr. Barbara Obermayer-Pietsch, Prof. Ciara O'Sullivan, Dr. Christoph W. Haudum, Dr. Josep Lluís Acero Sánchez), family, friends, colleagues, the funding organization of the project (Infineon Technologies - Austria, CBmed GmbH, Medizinische Universität Graz)and to our collaborators at Universitat Rovira i Virgili. I look forward to connecting with others who share this vision of improving healthcare through innovation. 🌟 #PhD #Doctorate #Research #Innovation #NextChapter #MetabolicHealth #AtHomeTesting #SelfTestingSolutions #MedizinischeMedizinischeMedizinischeMedizinischeMedizinische Universität Graz